Daniel Goldshtein, Sze Wah Samuel Chan
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR 0.58 (significant).
2. Grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group.
Evidence Rating Level : 1 (Excellent)
Study Rundown: Nivolumab, an anti-PD-1 antibody, combined with chemotherapy, has been used as neoadjuvant treatment for resectable non-small-cell lung cancer (NSCLC). Recently perioperative approaches, involving both neoadjuvant and adjuvant immunotherapy, have shown promising results in reducing disease relapse and improving overall survival...
May 20, 2024: 2 Minute Medicine